Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Judith de Vos‐Geelen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2578-1766; OpenAlex author ID A5031137165. Sources: OpenAlex.

Their work

Papers
76 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
168
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 6 papers · 2021: 11 papers · 2022: 7 papers · 2023: 8 papers · 2024: 7 papers · 2025: 17 papers · 2026: 18 papers

Papers 50 of 76

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. Last author DOI 10.1002/cam4.72306↗
  3. The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. Co-author DOI 10.1007/s00520-026-10568-3↗
  4. Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. Last author DOI 10.1016/j.ejca.2026.116263↗
  5. Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. Co-author DOI 10.1016/j.ejca.2026.116683↗
  6. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  7. Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study. Co-author DOI 10.1016/j.ejca.2026.116943↗
  8. The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116956↗
  9. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  10. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  11. Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer. Last author DOI 10.1016/j.esmogo.2026.100311↗
  12. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  13. Plasmin Generation Kinetics Reveal a Hyperfibrinolytic Phenotype in Patients with Pancreatic Ductal Adenocarcinoma First author DOI 10.1055/a-2925-6824↗
  14. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Co-author DOI 10.1093/bjsopen/zrag033↗
  15. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  16. Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. Last author DOI 10.1097/j.pain.0000000000004059↗
  17. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  18. CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. Co-author DOI 10.3390/cancers18111743↗
  19. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Co-author DOI 10.1002/ijc.35267↗
  20. Skeletal muscle is independently associated with grade 3-4 toxicity in advanced stage pancreatic ductal adenocarcinoma patients receiving chemotherapy. Co-author DOI 10.1016/j.clnesp.2024.11.004↗
  21. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. Co-author DOI 10.1016/j.eclinm.2024.103068↗
  22. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Last author DOI 10.1016/j.ejca.2025.115385↗
  23. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Co-author DOI 10.1016/j.ejca.2025.116065↗
  24. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  25. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  26. KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer. Co-author DOI 10.1016/j.medj.2025.100601↗
  27. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. Co-author DOI 10.1016/j.pan.2025.03.011↗
  28. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  29. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Co-author DOI 10.1038/s41467-025-66092-1↗
  30. Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. Co-author DOI 10.1038/s41598-025-94362-x↗
  31. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  32. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  33. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  34. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
  35. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  36. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  37. Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer. Co-author DOI 10.1016/j.jtha.2023.12.037↗
  38. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  39. Cellular Components Contributing to the Development of Venous Thrombosis in Patients with Pancreatic Cancer. Co-author DOI 10.1055/s-0043-1777304↗
  40. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  41. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  42. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  43. Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.04.017↗
  44. Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery. Co-author DOI 10.1016/j.hpb.2023.07.904↗
  45. Practice variation in venous resection during pancreatoduodenectomy for pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1016/j.surg.2023.06.012↗
  46. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient p… Co-author DOI 10.1080/0284186x.2023.2273898↗
  47. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  48. Impact of network treatment in patients with resected pancreatic cancer on use and timing of chemotherapy and survival. Co-author DOI 10.1093/bjsopen/zrad006↗
  49. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  50. Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care. Last author DOI 10.3390/cancers15143546↗

Closest collaborators

The 25 strongest of 168 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johanna W. Wilmink · 49 shared papers, 2018–2026 · strength 8.15
  2. Marc G. Besselink · 49 shared papers, 2016–2026 · strength 7.33
  3. Marjolein Y.V. Homs · 34 shared papers, 2020–2026 · strength 5.91
  4. Ignace H. J. T. de Hingh · 38 shared papers, 2016–2026 · strength 5.64
  5. Lydia G. van der Geest · 26 shared papers, 2018–2026 · strength 4.40
  6. Hanneke W.M. van Laarhoven · 26 shared papers, 2018–2026 · strength 4.31
  7. Bas Groot Koerkamp · 29 shared papers, 2018–2026 · strength 4.25
  8. Casper H.J. van Eijck · 28 shared papers, 2016–2026 · strength 4.14
  9. Hjalmar C. van Santvoort · 27 shared papers, 2018–2026 · strength 4.03
  10. Izaak Quintus Molenaar · 25 shared papers, 2016–2026 · strength 3.62
  11. Martijn W.J. Stommel · 22 shared papers, 2020–2026 · strength 3.51
  12. Bert A. Bonsing · 25 shared papers, 2016–2026 · strength 3.50
  13. Vincent Erwin de Meijer · 22 shared papers, 2020–2026 · strength 3.42
  14. Lois A. Daamen · 11 shared papers, 2023–2026 · strength 2.11
  15. Merlijn U.J.E. Graus · 10 shared papers, 2023–2026 · strength 2.10
  16. Aniek E. van Diepen · 7 shared papers, 2025–2026 · strength 1.81
  17. Jeanin Elise van Hooft · 10 shared papers, 2020–2026 · strength 1.69
  18. Pauline A. J. Vissers · 8 shared papers, 2020–2026 · strength 1.51
  19. Sebastiaan Festen · 12 shared papers, 2016–2026 · strength 1.47
  20. Geertjan van Tienhoven · 12 shared papers, 2016–2026 · strength 1.42
  21. Simone Augustinus · 7 shared papers, 2022–2026 · strength 1.39
  22. Ruth A.L. Willems · 6 shared papers, 2023–2026 · strength 1.36
  23. Stefan A.W. Bouwense · 7 shared papers, 2022–2026 · strength 1.30
  24. Gijs A. Patijn · 12 shared papers, 2016–2025 · strength 1.30
  25. Hugo ten Cate an · 5 shared papers, 2023–2026 · strength 1.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.